A multicenter, single-arm, open-label study of the efficacy and safety of CC-5013 [lenalidomide] monotherapy in RBC [red blood cell] transfusion-dependent subjects with myelodysplastic syndromes

Trial Profile

A multicenter, single-arm, open-label study of the efficacy and safety of CC-5013 [lenalidomide] monotherapy in RBC [red blood cell] transfusion-dependent subjects with myelodysplastic syndromes

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2013

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov (NCT00064974).
    • 03 Apr 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov (NCT00064974).
    • 11 Aug 2009 Actual end date (Aug 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top